Sagimet BiosciencesSTU:0O2 +1.66%10 Return-on-Tangible-Equity is -40.11% as of Mar. 2026. GuruFocus rates STU:0O2 with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 1,202 Biotechnology companies, Sagimet Biosciences ranks better than 53.24% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Sagimet Biosciences's annualized net income for the quarter that ended in Mar. 2026 was €-36.85 Mil. Sagimet Biosciences's average shareholder tangible equity for the quarter that ended in Mar. 2026 was €91.87 Mil. Therefore, Sagimet Biosciences's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -40.11%.
The historical rank and industry rank for Sagimet Biosciences's Return-on-Tangible-Equity or its related term are showing as below:
STU:0O2'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -38.2 Med: -37.56 Max: -36.12
Current: -36.12
During the past 7 years, Sagimet Biosciences's highest Return-on-Tangible-Equity was -36.12%. The lowest was -38.20%. And the median was -37.56%.
STU:0O2's Return-on-Tangible-Equity is ranked better than 53.24% of 1202
companies
in the Biotechnology industry
Industry Median: -42.435
vs STU:0O2: -36.12
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Sagimet Biosciences Return-on-Tangible-Equity Related Terms
Sagimet Biosciences Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Sagimet Biosciences's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:0O2 vs EDIT, AUTL, FBRX: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Sagimet Biosciences's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sagimet Biosciences Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sagimet Biosciences's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Sagimet Biosciences's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -40.11% mean?
Sagimet Biosciences (STU:0O2) has a Return-on-Tangible-Equity of -40.11% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sagimet Biosciences and its competitors. According to the industry distribution chart, Sagimet Biosciences ranks #562 out of 1202 companies in the Biotechnology industry, placing it in the top 46.8%.
Is Sagimet Biosciences' Return-on-Tangible-Equity too high?
Sagimet Biosciences' current Return-on-Tangible-Equity is -40.11%. Based on the distribution chart, Sagimet Biosciences ranks #562 out of 1202 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sagimet Biosciences has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Sagimet Biosciences' Return-on-Tangible-Equity compare to EDIT and AUTL?
According to the Biotechnology industry distribution chart, Sagimet Biosciences ranks #562 out of 1202 companies for Return-on-Tangible-Equity. This puts Sagimet Biosciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sagimet Biosciences and its competitors. Sagimet Biosciences's current Return-on-Tangible-Equity is -40.11%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sagimet Biosciences stock overvalued right now?
Sagimet Biosciences (STU:0O2) has a current Return-on-Tangible-Equity of -40.11%. The current Return-on-Tangible-Equity is -40.11%. Sagimet Biosciences' overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Sagimet Biosciences (STU:0O2), the current Return-on-Tangible-Equity is -40.11% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
10GF Score
Get the complete analysis for STU:0O2
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:0O2 has been successfully added to your 
